


Backgrounder: Ankylosing Spondylitis

For Media Use Only

What is ankylosing spondylitis?

Ankylosing spondylitis (AS) is a common type of spondyloarthritis (SpA), a family of long-term diseases of joints (inflammatory disease)¹. AS is a painful, progressively debilitating condition caused by inflammation of the spine leading to irreversible damage that significantly reduces patients' mobility and quality of life².

AS occurs in approximately 1% of the general population and typically affects young men and women aged 25 or older^{3,4}. Certain genetic factors increase a person's risk of developing AS by more than 50%⁵.



Flexion contractures of the hand in a patient with ankylosing spondylitis



A young man with severe ankylosing spondylitis, showing outward curvature of the spine due to fusion of the vertebrae

What is the immune system's role in AS?

The immune system produces certain proteins called cytokines, which serve as “messengers” that coordinate communication between immune cells in response to an infection⁶. One of these cytokines, interleukin-17A (IL-17A), has been identified as playing a key role in a number of immune-mediated diseases such as AS⁶.

Higher concentrations of IL-17A have been found in areas surrounding the bones and joints in people suffering from AS, particularly in the fluid and lining of the joints⁷⁻⁹.

- IL-17A acts as signal to infection-fighting cells, triggering an inflammatory response that results in bone erosion and new bone formation to replace lost elastic tissue in areas surrounding the bones and joints⁷⁻⁹.
- Infection-fighting cells continue to release IL-17A, leading to further inflammation and ultimately new bone reformation that causes bones to grow together into a rigid structure⁷⁻⁹.

What are the physical and psychological effects of AS?

Up to 70% of patients with severe AS can develop spinal fusion (bones grow together), which significantly reduces mobility and quality of life^{2,10,11}. In particular, professional performance is significantly affected, with 78% more likely to shorten their working hours and therefore risk losing their jobs¹¹. Because people can no longer effectively undertake day-to-day activities, some may also develop anxiety and depression¹².

What are the unmet needs in AS?

Patients with AS have very few therapeutic options available to them¹³. In patients who do not respond to non-steroidal anti-inflammatory drugs (NSAIDs), anti-TNF (tumor-necrosis-factor) medicines are the only currently available biologic treatment alternative, but are not effective for all patients¹³. Up to 40% of people receiving anti-TNF therapy, the current standard of treatment for more severe disease, fail to achieve sufficient clinical improvement¹³. There remains significant unmet need in AS for safer, faster-acting and longer-lasting treatments than those currently available¹³.

References

1. American College of Rheumatology (ACR) website. "Spondylarthritis (Spondylarthropathy)." [http://www.rheumatology.org/Practice/Clinical/Patients/Diseases_And_Conditions/Spondylarthritis_\(Spondylarthropathy\)/](http://www.rheumatology.org/Practice/Clinical/Patients/Diseases_And_Conditions/Spondylarthritis_(Spondylarthropathy)/). Accessed October 2014.
2. Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. *Ann Rheum Dis*. 2002;61(Suppl III):iii8-iii18.
3. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. *Arthritis Rheum*. 1998;41(1):58-67.
4. Feldtkeller E, Khan M, Van Der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. Positive patients with ankylosing spondylitis. *Rheumatology International*. 2003;23(2):61-66.
5. Brown MA. Progress in studies of the genetics of ankylosing spondylitis. *Arthritis Res Ther*. 2009;11:254.
6. Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. *Ann Rheum Dis*. 2012. [Epub ahead of print]
7. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondyloarthritis. *Arthritis Rheum*. 2012;64:99-109.
8. Taylan A, Sari I, Kozaci DL, et al. Evaluation of the T helper 17 axis in ankylosing spondylitis. *Rheumatol Int*. 2012;32:2511-2515.
9. Mei Y, Pan F, Gao J, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. *Clin Rheumatol*. 2011;30:269-273.
10. Lories R. The balance of tissue repair and remodeling in chronic arthritis. *Nat Rev Rheumatol*. 2011;7:700-07.
11. Barkham N, Kong KO, & Tennant A. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. *Rheumatology*. 2005;44:1277-81.
12. Martindale J, Smith J, Sutton CJ, et al. Disease and psychological status in ankylosing spondylitis. *Rheumatology (Oxford)*. 2006;45(10):1288-93.
13. Dougados M, Baeten D. Spondyloarthritis. *Lancet*. 2011; 377:2127-37.

###



Novartis Pharma AG
CH-4002 Basel, Switzerland
©2014 Novartis Pharma AG
ASPRO01/1114